Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 10, 2023
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
[ Mon, Apr 10th 2023
] - WOPRAI
Ashwani Verma Maintained (UTHR) at Strong Buy with Decreased Target to $310 on, Apr 10th, 2023
Ashwani Verma of UBS, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Decreased Target from $330 to $310 on, Apr 10th, 2023.
Ashwani has made no other calls on UTHR in the last 4 months.
There are 3 other peers that have a rating on UTHR. Out of the 3 peers that are also analyzing UTHR, 0 agree with Ashwani's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Ashwani
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $300 on, Thursday, February 23rd, 2023
- Jessica Fung of "JP Morgan" Maintained at Buy with Increased Target to $280 on, Thursday, February 23rd, 2023
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $300 on, Wednesday, January 11th, 2023
